Compare OPAD & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | KYNB |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | 140 | 34 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 27.1M |
| IPO Year | N/A | N/A |
| Metric | OPAD | KYNB |
|---|---|---|
| Price | $5.32 | $7.43 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.83 | N/A |
| AVG Volume (30 Days) | ★ 216.4K | 34.0K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $6.32 |
| 52 Week High | $6.35 | $9.58 |
| Indicator | OPAD | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 75.68 | 69.70 |
| Support Level | $0.63 | $6.66 |
| Resistance Level | $5.53 | $7.95 |
| Average True Range (ATR) | 0.40 | 0.39 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 80.80 | 75.32 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.